Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial. Journal Abstract

Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial.

Publication Date: 2024 Sep 01

Full Text Sources

Authors

Babak B Navi; Cenai Zhang; Benjamin Miller; Mary Cushman; Scott E Kasner; Mitchell S V Elkind; David L Tirschwell; W T Longstreth; Richard A Kronmal; Morin Beyeler; Jordan Elm; Richard M Zweifler; Joseph Tarsia; Carlo W Cereda; Giovanni Bianco; Gianluca Costamagna; Patrik Michel; Joseph P Broderick; David J Gladstone; Hooman Kamel; Christopher Streib

Abstract

OBJECTIVE

Approximately 10% to 15% of ischemic strokes are associated with cancer; cancer-associated stroke, particularly when cryptogenic, is associated with high rates of recurrent stroke and major bleeding. Limited data exist on the safety and efficacy of different antithrombotic strategies in patients with cancer and cryptogenic stroke.

Source

JAMA neurology

Pub Types(s)

Journal Article

Language

English

PubMed ID

39133474